PUT - SPRINTER OPEN END - NOVO-NORDISK B | Market Closed - Boerse Frankfurt Warrants 11:13:03 31/05/2024 pm IST | ||
| 3.19 EUR | +0.31% |
|
| 1 month | -5.90% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 3.19 | +0.31% |
| 30/24/30 | 3.18 | -3.34% |
| 29/24/29 | 3.29 | +1.23% |
| 28/24/28 | 3.25 | +4.84% |
| 27/24/27 | 3.1 | +5.44% |
Real-time Boerse Frankfurt Warrants
Last update May 31, 2024 at 11:13 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD1XAZ |
| ISIN | DE000VD1XAZ6 |
| Date issued | 08/03/2024 |
| Strike | 1,158 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.51 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.28 € |
|---|---|
| Lowest since issue | 2.89 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Certificates
- Certificat
